Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Esophageal cancer食管癌

ICD-10: C15 — Malignant neoplasm of oesophagus

Group: Cancer Specialty: Esophageal Surgery, Thoracic Surgery

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
食管癌
English name
Malignant neoplasm of oesophagus

Values written in Chinese are quoted as published by the source.

Also known as

  • ESCC
  • Esophageal squamous cell carcinoma

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 85000 – 95000 CNY Condition package price 病种打包全包价 2020–2021
Radiotherapy 放疗 42000 – 53000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 7250 – 10500 CNY Condition package price 病种打包全包价 2020–2021
Targeted therapy 靶向 85000 – 105000 CNY Per-item price 项目价 2025
Immunotherapy 免疫 32043 – 43803 CNY Per-item price 项目价 2024–2025

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 105000 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 27.9% 95% CI 27.5–28.2

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    1 more published study

    PubMed indexes 3 papers on this condition that name this hospital.

    Also ranked: Medical Oncology #1, Urology nominated in the Fudan list.

  2. Shanghai Chest Hospital上海市胸科医院（暨上海交通大学医学院附属胸科医院）

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    4 more published studies

    PubMed indexes 6 papers on this condition that name this hospital.

  3. Shanghai Pulmonary Hospital上海市肺科医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Respiratory Medicine nominated in the Fudan list.

  4. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #3, Urology #2 (tied), Otorhinolaryngology #8 in the Fudan list.

  5. First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院

    Guangzhou 广州市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: Respiratory Medicine #1, Urology nominated in the Fudan list.

  6. Zhongshan Hospital复旦大学附属中山医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #2, Gastroenterology #9, Respiratory Medicine #6 in the Fudan list.

  7. Peking University People's Hospital北京大学人民医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #10, Gynecology #7, Otorhinolaryngology nominated in the Fudan list.

  8. Ruijin Hospital上海交通大学医学院附属瑞金医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

    Also ranked: General Surgery #4, Respiratory Medicine #5, Infectious Diseases 传染感染 #6 in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Esophageal cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study Anhui Provincial Hospita

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT05833594

  2. Study A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06869226

  3. Study Comparing Hypofractionated Concurrent Chemoradiotherapy Versus Conventional Fractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Open-Label, Randomized Phase II Clinical Trial

    Lead investigator
    Hui Liu · Professor
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT06912074

  4. Study A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.

    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT06022861

  5. Study A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

    Hospital
    Nanfang Hospital
    Status
    Recruiting
    Registry
    NCT06843889
27 more registered studies

  1. Study Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study

    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT04415853

  2. Study A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

    Hospital
    Jilin Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07700667

  3. Study Neoadjuvant Immunotherapy Plus Chemotherapy and Anlotinib Versus Immunotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced ESCC

    Lead investigator
    Mengxia Li
    Status
    Recruiting
    Registry
    NCT06354530

  4. Study A Single-arm, Single-center, Exploratory Clinical Study of Adebrelimab Combined With Neoadjuvant Chemotherapy for the Treatment of Esophageal Squamous Cell Carcinoma

    Hospital
    The Second Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT07430579

  5. Study Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

    Hospital
    Jiangsu Cancer Hospital
    Status
    Recruiting
    Registry
    NCT04519905

  6. Study Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    Lead investigator
    Ning Jiang, M.D./Ph.D. · Jiangsu Cancer Institute & Hospital
    Hospital
    Jiangsu Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07435454

  7. Study Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

    Lead investigator
    Benhua Xu · Director,Radiation Oncology
    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT03734952

  8. Study Perioperative Immunoagent (Tislelizumab) Plus Chemotherapy for Locally Advanced Resectable Thoracic Oesophageal Squamous Cell Carcinoma Trail:A Prospective Single-arm,Phase II Study (PILOT Trail)

    Lead investigator
    Guo Xufeng · Principal Investigator
    Hospital
    Shanghai Chest Hospital
    Status
    Recruiting
    Registry
    NCT06056336

  9. Study Efficacy and Safety of Ivonescimab Combined With Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma: A Prospective, Single-Center, Single-Arm Phase II Clinical Study

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT07188103

  10. Study Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

    Lead investigator
    Yongshun Chen · professor
    Hospital
    Renmin Hospital of Wuhan University
    Status
    Recruiting
    Registry
    NCT05894369

  11. Study Chemoradiation Versus Chemotherapy in Combination with Tislelizumab As First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Low PD-L1 Expression (RENMIN-236): Multicentre, Randomised, Phase 3 Trial

    Lead investigator
    Yongshun Chen · Professor
    Hospital
    Renmin Hospital of Wuhan University
    Status
    Recruiting
    Registry
    NCT05919030

  12. Study A Prospective, Randomized Controlled Clinical Trial of Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma

    Lead investigator
    Peng Lin · Clinical Professor
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT04174079

  13. Study Adjuvant Esophagectomy Versus Chemoradiation for Patients With Clinical Stage N0 and Pathological Stage T1b (After Endoscopic Submucosal Dissection, ESD) Esophageal Squamous Cell Carcinoma (Ad-ESD Trial): a Multicentric, Open Label, Randomized Trial

    Lead investigator
    Zhigang Li · Chief of Department of Esophageal Surgery, Deputy of Department of Thoracic Surgery
    Hospital
    The First Affiliated Hospital of Nanchang University
    Status
    Recruiting
    Registry
    NCT04135664

  14. Study An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC)

    Hospital
    Cancer Hospital of Chinese Academy of Medical Sciences
    Status
    Recruiting
    Registry
    NCT07484724

  15. Study The Effect of Chronic Stress on Efficacy of Immune Checkpoint Inhibitors in Patients With Newly Diagnosed Esophageal Cancer

    Lead investigator
    Fang Wu · chief physician
    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT05967910

  16. Study Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer

    Lead investigator
    Chen Chen · Associate Professor
    Hospital
    Second Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT07063901

  17. Study A Single-center, Prospective Cohort Study of Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

    Hospital
    Zhongshan Hospital
    Status
    Recruiting
    Registry
    NCT05740995

  18. Study Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology

    Lead investigator
    Qujinrong · Clinical Professor
    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07203690

  19. Study Indocyanine Green-guided Sentinel Lymph Node Dissection Versus Systematic Lymph Node Dissection in cN0 Esophageal Squamous Cell Carcinoma: a Multicenter, Prospective, Non-inferiority Randomized Controlled Trial

    Hospital
    Fujian Medical University Union Hospital
    Status
    Not yet recruiting
    Registry
    NCT07788001

  20. Study Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study

    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07034118

  21. Study A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Safety and Efficacy of Anlotinib Hydrochloride Combined With Benmelstobart Versus Toripalimab Combined With Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma Harboring Specific Gene Mutations

    Lead investigator
    Feng Wang · professor
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Not yet recruiting
    Registry
    NCT07446335

  22. Study Development and Multicenter Validation of Standardized MRI Acquisition and Structured Reporting for Primary Esophageal Squamous Cell Carcinoma: A Dual-Cohort Study of T Staging and Tumor Regression Grading

    Lead investigator
    Xiangbo Wan · Chief Physician and Principal Investigator
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Not yet recruiting
    Registry
    NCT07769658

  23. Study Construction of Artificial Intelligence Model for Esophageal Cancer Digital Twin Patients and Drug Efficacy Simulation Verification Based on Supercomputing Platform and Multi-Omics Data

    Lead investigator
    YanZheng,MD · Director
    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07757022

  24. Study Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter, Phase III Clinical Trial

    Lead investigator
    YanZheng,MD · Director of Clinical Trials Center
    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07332221

  25. Study Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

    Lead investigator
    Qujinrong · Clinical Professor
    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06833775

  26. Study A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06745193

  27. Study Prospective Single-Arm Study of QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer

    Lead investigator
    Hecheng Li M.D., Ph.D · Chair of Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT07283991

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 28 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Shanghai Pulmonary Hospital上海市肺科医院 Shanghai 上海市 Thoracic Surgery 胸外科 Level B https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
Shanghai Chest Hospital上海市胸科医院（暨上海交通大学医学院附属胸科医院） Shanghai 上海市 Thoracic Surgery 胸外科专业 Level B https://www.shxkyy.com/hz/list/190/1400.html
Zhongshan Hospital复旦大学附属中山医院 Shanghai 上海市 Thoracic Surgery 胸外科 Level B https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.cicams.ac.cn/news/401.html
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Beijing Hospital北京医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University People's Hospital北京大学人民医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital北京大学第一医院 Beijing 北京市 Thoracic Surgery 胸外科 Level B https://www.pkufh.com/Html/News/Articles/64494.html
West China Hospital, Sichuan University四川大学华西医院 Chengdu 成都市 Thoracic Surgery 胸外科 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院 Tianjin 天津市 Thoracic Surgery 胸外科 Level B https://www.tjmuch.com/yygk/yyjj/index_yg.shtml
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Thoracic Surgery 胸外科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Shandong Provincial Qianfoshan Hospital山东省千佛山医院 Jinan 济南市 Thoracic Surgery 胸外科 Level A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 Guangzhou 广州市 Thoracic Surgery 胸外科 Level B https://sysucc.org.cn/department/introduction/41
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Thoracic Surgery 胸外科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
Guangdong Provincial People's Hospital广东省人民医院 Guangzhou 广州市 Thoracic Surgery 胸外科 Level B https://static.nfnews.com/content/202503/22/c11108498.html
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 Guangzhou 广州市 Thoracic Surgery 胸外科 Level B https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
Jiangsu Cancer Hospital江苏省肿瘤医院 Nanjing 南京市 Thoracic Surgery 胸外科 Level B https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Henan Cancer Hospital河南省肿瘤医院 Zhengzhou 郑州市 Thoracic Surgery 胸外科 Level B https://www.anti-cancer.com.cn/Html/News/Articles/13202.html
First Affiliated Hospital of Zhengzhou University郑州大学第一附属医院 Zhengzhou 郑州市 Thoracic Surgery 胸外科 Level C Not published
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 Thoracic Surgery 胸外科 Level B https://www.whuh.com/kxyj/xkjs/gjlczdzk/2.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Thoracic Surgery 胸外科 Level B https://www.tjh.com.cn/contents/934/27291.html
Renmin Hospital of Wuhan University武汉大学人民医院 Wuhan 武汉市 Thoracic Surgery 胸外科 Level B https://www.rmhospital.com/article/id/16939.html
Second Xiangya Hospital of Central South University中南大学湘雅二医院 Changsha 长沙市 Thoracic Surgery 胸外科 Level B https://www.xyeyy.com/655/656/664/
Shengjing Hospital中国医科大学附属盛京医院 Shenyang 沈阳市 Thoracic Surgery 胸外科 Level B https://www.sj-hospital.org/sjweekly/resfile/2024-01-26/16/sjzk-20240126-016.pdf
First Hospital of China Medical University中国医科大学附属第一医院 Shenyang 沈阳市 Thoracic Surgery 胸外科 Level A https://wsjk.ln.gov.cn/wsjk/index/gsgg/D6FB5218203A456D9540155A2D928D84/index.shtml
Liaoning Cancer Hospital辽宁省肿瘤医院 Shenyang 沈阳市 Thoracic Surgery 胸外科 Level B https://www.lnchi.org.cn/ch/hospital/biref/index.html
The First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 Chongqing 重庆市 Thoracic Surgery 胸外科 Level B https://www.hospital-cqmu.com/gzb/yygk/yyjj.htm
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院 Xi'an 西安市 Thoracic Surgery 胸外科 Level B http://www.dyyy.xjtu.edu.cn/info/41461/122341.htm

28 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 9 ICD codes
Version Code Name in that version
ICD-10-WHO C15 Malignant neoplasm of oesophagus
ICD-10-WHO C15.0 Cervical part of oesophagus
ICD-10-WHO C15.1 Thoracic part of oesophagus
ICD-10-WHO C15.2 Abdominal part of oesophagus
ICD-10-WHO C15.3 Upper third of oesophagus
ICD-10-WHO C15.4 Middle third of oesophagus
ICD-10-WHO C15.5 Lower third of oesophagus
ICD-10-WHO C15.8 Overlapping lesion of oesophagus
ICD-10-WHO C15.9 Oesophagus, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24